证券之星消息，7月29日中药板块较上一交易日上涨1.0%，佛慈制药领涨。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002317 众生药业 | | 3.08亿 | 13.62% | -2.09亿 | -9.25% | -9887.67万 | -4.37% | | 300158 振东制药 | | 9631.85万 | 6.34% | -3070.18万 | -2.02% | -6561.68万 | -4.32% | | 686000 | 九芝堂 | 7562.48万 | 11.69% | 2336.98万 | 3.61% | -9899.45万 | -15.30% | | 002907 | 华森制药 | 6726.09万 | 9.79% | -650.70万 | -0.95% | -6075 ...

Core Viewpoint - The article highlights the successful implementation of intelligent manufacturing and industrial transformation in Wuhan, exemplified by the Ma Yinglong company, which has achieved significant efficiency and quality improvements through automation and smart production lines [1][7]. Government Initiatives - Wuhan has initiated a "Special Action for Industrial Intelligent Transformation" since 2019, aiming to develop a four-tier model from digital production lines to national-level digital leading enterprises [2]. - The government has introduced 20 special policies to financially support industrial enterprises in technology upgrades, reducing the investment threshold for smart transformation from 20 million to 5 million yuan [3]. - A dual approach combining policy support and financial tools has been established, including a 20 billion yuan industrial transformation loan fund and a 15 billion yuan financial leasing fund [5][6]. Market Response - The Ma Yinglong smart factory has integrated 5G, industrial internet, and automation, achieving a 30% increase in production efficiency and a 100% pass rate for product quality [7][8]. - Wuhan has cultivated 300 digital production lines, 122 smart demonstration workshops, and 30 benchmark smart factories, showcasing the city's commitment to intelligent manufacturing [8]. Industrial Growth - Wuhan's industrial investment has seen a 12.1% year-on-year increase from January to May 2023, maintaining double-digit growth for 16 consecutive months, with industrial investment accounting for 27.1% of total investment [11][12]. - Key industries such as automotive manufacturing and non-metallic mineral products have experienced substantial growth, with increases of 44% and 91.3% respectively [12]. Future Outlook - The city is focused on leveraging new technologies like AI and 5G to further enhance industrial transformation, aiming to transition from "Wuhan Manufacturing" to "Wuhan Intelligent Manufacturing" [13].

Meeting Overview - The shareholders' meeting of Mayinglong Pharmaceutical Group Co., Ltd. was held on June 30, 2025 [1] - The meeting was convened by the board of directors and chaired by Chairman Chen Ping, utilizing a combination of on-site and online voting methods [1][3] Voting Results - All resolutions presented at the meeting were approved, with significant support from shareholders [2][3] - For the first resolution, 206,034,314 A-shares voted in favor, representing 99.7154% of the votes [1] - The second resolution received 206,029,914 A-shares in favor, accounting for 99.7132% [1] - The third resolution had 206,030,114 A-shares in favor, which is 99.7133% [1] - The fourth resolution also passed with 206,034,214 A-shares in favor, representing 99.7153% [1] Legal Compliance - The meeting's procedures were confirmed to comply with legal regulations and the company's articles of association, ensuring the legitimacy of the convening and voting processes [3]

证券代码：600993 证券简称：马应龙 公告编号：2025-016 马应龙药业集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 6 月 30 日 (二) 股东大会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 335 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 206,622,314 | | 3、出席会议的股东所持有表决权股份数占公司有表 | 47.9342 | | 决权股份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长陈平先生主持，采取现场投票和网 络投票结合的表决方式，符合《公司法》及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席 ...

湖北瑞通天元律师事务 HUBEI RUITONG TIANYUAN LAW 湖北瑞通天元律师事务所 关于马应龙药业集团股份有限公司 二〇二四年年度股东大会的法律意见书 (2025) 鄂瑞天律非诉字第 0655 号 致 马应龙药业集团股份有限公司: 湖北瑞通天元律师事务所接受马应龙药业集团股份有限公司(以 下简称"公司")的委托,指派柳平律师、许畅律师(以下简称"本律 师"）出席了公司二〇二四年年度股东大会(以下简称"本次股东大 会"),并依法进行见证。现根据《中华人民共和国公司法》、《上市公 司股东会规则》等法律法规和规范性文件以及《公司章程》的有关规 定,就公司本次股东大会的有关事宜出具法律意见书。 本律师对公司本次股东大会的召集、召开程序的合法性、本次股 东大会召集人资格的合法有效性、出席本次会议人员资格的合法有效 性及会议表决程序、表决结果的合法有效性,发表法律意见。 本律师依据对法律意见书出具日以前已经发生或存在的事实的 了解及对现行相关法律、法规的理解发表法律意见。 本律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精 神,对公司提供的出具法律意见书所必须的、全部的、真实的有关公 司本次股东大会 ...

Core Viewpoint - The company has achieved significant growth in its financial performance, with a focus on enhancing operational efficiency and expanding its market presence in the pharmaceutical industry. Group 1: Financial Performance - The net profit attributable to the parent company reached 528 million yuan, representing a year-on-year increase of 19.14%, while the net profit excluding non-recurring gains and losses was 511 million yuan, up 44.98% year-on-year [2]. - The main business revenue from the pharmaceutical industry was 2.161 billion yuan, reflecting a year-on-year growth of 17.82% [3]. - The medical service segment reported a revenue of 449 million yuan, marking a year-on-year increase of 30.15% [9]. Group 2: Business Strategy and Operations - The company is consolidating its core advantages in the anorectal field and has launched a new series of sanitary wet wipes targeting anal care, enhancing its competitive edge [4]. - The company has strengthened its brand marketing through various channels, including content marketing and strategic partnerships, to expand its market reach [5]. - The company is focusing on optimizing its research and development structure, particularly in strategic areas such as anorectal, ophthalmology, and dermatology, with multiple projects making progress [6]. Group 3: Governance and Compliance - The board of directors has held six meetings during the reporting period, reviewing 23 proposals, including regular reports and profit distribution [10]. - The independent directors have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations while maintaining the interests of all shareholders [23][24]. - The supervisory board has conducted effective oversight of the company's operations, financial status, and compliance with internal controls [20][21]. Group 4: Future Outlook - The pharmaceutical industry is expected to face stricter regulations and price governance, necessitating adjustments in market and pricing strategies [14]. - The retail pharmacy sector is undergoing transformation, with opportunities arising from the government's focus on enhancing health promotion functions [15]. - The company aims to continue its focus on the health and wellness market, leveraging advancements in artificial intelligence to enhance operational efficiency and service innovation [16][18].

马应龙药业集团股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 2024 年年度股东大会会议资料 马应龙药业集团股份有限公司 股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 效率，保证股东大会的顺利进行，根据中国证监会《上市公司股东会 规则》、《公司章程》及有关法律法规的要求，特制订本须知。 一、董事会以维护全体股东的合法权益、确保大会正常秩序和议 事效率为原则，认真履行《公司章程》中规定的职责。 二、股东参加股东大会依法享有发言权、质询权、表决权等权利。 股东参加股东大会履行其法定义务，不得侵犯其他股东的合法权益。 三、股东发言应举手示意，并按照会议的安排进行。 四、会议进行中接受股东（或其授权代表）发言或提问。股东每 次发言或提问应围绕本次会议议题进行，简明扼要，时间不超过 3 分 钟。 五、股东要求发言时不得打断会议报告人的报告或其他股东的发 言，股东提问和发言不得超出本次会议议案范围。股东违反上述规定 的，大会主持人有权加以制止或拒绝。 六、未经公司董事会同意，任何人员不得摄像、录音、拍照。如 有违反，大会组织方有权加以制止。 2 2024 年年度股东大 ...

Group 1 - Mayinglong Pharmaceutical Group Co., Ltd. has experienced a decline for six consecutive trading days, with a cumulative drop of -7.23% [1] - The company, founded in 1582, is recognized as a "Time-honored Brand" in China, maintaining operations for 440 years [1] - Two funds under China Merchants Jinling Fund Management Co., Ltd. have entered the top ten shareholders of Mayinglong, with both funds reducing their holdings in the first quarter of this year [1] Group 2 - The China Merchants Jinling New Vitality Flexible Allocation Mixed Fund has achieved a year-to-date return of 4.51%, ranking 728 out of 2246 in its category [2] - The China Merchants Jinling New Growth Mixed Fund has a year-to-date return of 4.33%, ranking 2172 out of 4426 in its category [2] - The fund managers for these funds are Yang Hao and Wang Chong, with Yang managing the New Vitality fund since November 2016 and Wang managing the New Growth fund since October 2014 [5][7] Group 3 - Yang Hao has a cumulative tenure of 9 years and 304 days at China Merchants Jinling Fund Management Co., Ltd., with a best performance return of 123.40% for the New Vitality fund [6] - Wang Chong has a cumulative tenure of 10 years and 236 days, with a best performance return of 292.29% for the New Growth fund [7] - China Merchants Jinling Fund Management Co., Ltd. was established in August 2005, with major shareholders including China Communications Bank (65%) and Schroders Investment Management (30%) [8]

Core Points - The controlling shareholder, China Baoan Group, holds a total of 126,163,313 shares in the company, representing 29.27% of the total share capital [1] - A total of 40,000,000 shares were released from pledge, which accounts for 31.70% of the shares held by China Baoan and 9.28% of the company's total share capital [1] - After the release, China Baoan has 50,000,000 shares still pledged, which is 39.63% of its holdings and 11.60% of the company's total share capital [1] - The release of the pledged shares occurred on June 12, 2025, and there are currently no plans for subsequent pledges of the released shares [1]

证券代码：600993 证券简称：马应龙 公告编号：临 2025-015 2025 年 6 月 13 日，马应龙药业集团股份有限公司（以下简称"公司"或"本 公司"）接控股股东中国宝安集团股份有限公司（以下简称"中国宝安"）函告， 2025 年 6 月 12 日中国宝安在中国证券登记结算有限责任公司与中国民生银行股 份有限公司深圳分行办理了本公司 40,000,000 股无限售流通股解除质押手续，具 体情况如下： | 股东名称 | 中国宝安集团股份有限公司 | | | | --- | --- | --- | --- | | 本次解除质押股份（股） | 40,000,000 | | | | 占其所持股份比例（%） | 31.70 | | | | 占公司总股本比例（%） | 9.28 | | | | 解除质押时间 | 2025 年 6 月 | 12 | 日 | | 持股数量（股） | 126,163,313 | | | | 持股比例（%） | 29.27 | | | | 剩余被质押股份数量（股） | 50,000,000 | | | | 剩余被质押股份数量占其所持股份比例（%） | 39.63 | | | 1 | ...